These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24419416)

  • 21. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
    Han G; Bi J; Tan W; Wei X; Wang X; Ying X; Guo X; Zhou X; Hu D; Zhen W
    Oncotarget; 2016 Aug; 7(35):56998-57010. PubMed ID: 27486770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor.
    Takano K; Kinoshita M; Takagaki M; Sakai M; Tateishi S; Achiha T; Hirayama R; Nishino K; Uchida J; Kumagai T; Okami J; Kawaguchi A; Hashimoto N; Nakanishi K; Imamura F; Higashiyama M; Yoshimine T
    Neuro Oncol; 2016 May; 18(5):716-24. PubMed ID: 26519739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGFR sequence variations and real-time quantitative polymerase chain reaction analysis of gene dosage in brain metastases of solid tumors.
    Franco-Hernandez C; Martinez-Glez V; Arjona D; de Campos JM; Isla A; Gutierrez M; Vaquero J; Rey JA
    Cancer Genet Cytogenet; 2007 Feb; 173(1):63-7. PubMed ID: 17284372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small-cell carcinoma in the setting of pulmonary adenocarcinoma: new insights in the era of molecular pathology.
    Norkowski E; Ghigna MR; Lacroix L; Le Chevalier T; Fadel É; Dartevelle P; Dorfmuller P; Thomas de Montpréville V
    J Thorac Oncol; 2013 Oct; 8(10):1265-71. PubMed ID: 24457237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between EGFR gene mutation and local metastasis of resectable lung adenocarcinoma.
    Nie Y; Gao W; Li N; Chen W; Wang H; Li C; Zhang H; Han P; Zhang Y; Lv X; Xu X; Liu H
    World J Surg Oncol; 2017 Mar; 15(1):55. PubMed ID: 28253871
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
    Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma.
    Li B; Sun SZ; Yang M; Shi JL; Xu W; Wang XF; Song MM; Chen HM
    J Neurooncol; 2015 Aug; 124(1):79-85. PubMed ID: 26050023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma.
    Tomonaga N; Nakamura Y; Yamaguchi H; Ikeda T; Mizoguchi K; Motoshima K; Doi S; Nakatomi K; Iida T; Hayashi T; Nagayasu T; Tsukamoto K; Kohno S
    Clin Lung Cancer; 2013 Sep; 14(5):521-6. PubMed ID: 23786997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.
    Lee DW; Shin DY; Kim JW; Keam B; Kim TM; Kim HJ; Kim DW; Wu HG; Paek SH; Kim YW; Heo DS; Kim DG; Lee SH
    Lung Cancer; 2014 Dec; 86(3):363-8. PubMed ID: 25453849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex-specific incidence of EGFR mutation and its association with age and obesity in lung adenocarcinomas: a retrospective analysis.
    Kim HR; Kim SY; Kim CH; Yang SH; Lee JC; Choi CM; Na II
    J Cancer Res Clin Oncol; 2017 Nov; 143(11):2283-2290. PubMed ID: 28689332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Brain Metastases in Patients With Non-Small Cell Lung Cancer and No Brain Metastases at Initial Staging Evaluation: Cumulative Incidence and Risk Factor Analysis.
    Kim M; Suh CH; Lee SM; Park JE; Kim HC; Kim SO; Aizer AA; Yanagihara TK; Bai HX; Guenette JP; Huang RY; Kim HS
    AJR Am J Roentgenol; 2021 Nov; 217(5):1184-1193. PubMed ID: 34037408
    [No Abstract]   [Full Text] [Related]  

  • 35. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of EGFR mutation status in lung adenocarcinoma specimens with different proportions of tumor cells using two methods of differential sensitivity.
    Han HS; Lim SN; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Son SM; Choi SY; Lee HC; Lee OJ
    J Thorac Oncol; 2012 Feb; 7(2):355-64. PubMed ID: 22157369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma.
    Ohtsuka K; Ohnishi H; Furuyashiki G; Nogami H; Koshiishi Y; Ooide A; Matsushima S; Watanabe T; Goya T
    J Thorac Oncol; 2006 Oct; 1(8):787-95. PubMed ID: 17409961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
    Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y
    Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.
    Marks JL; Broderick S; Zhou Q; Chitale D; Li AR; Zakowski MF; Kris MG; Rusch VW; Azzoli CG; Seshan VE; Ladanyi M; Pao W
    J Thorac Oncol; 2008 Feb; 3(2):111-6. PubMed ID: 18303429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis.
    Fujimoto D; Ueda H; Shimizu R; Kato R; Otoshi T; Kawamura T; Tamai K; Shibata Y; Matsumoto T; Nagata K; Otsuka K; Nakagawa A; Otsuka K; Katakami N; Tomii K
    Clin Exp Metastasis; 2014 Jun; 31(5):543-51. PubMed ID: 24682604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.